ImmuneOncia aims to develop immuno-oncology therapeutics

to transform the standard of care in cancer treatment

  • IR/PR
  • Disclosures

Disclosures

Submission Date Disclosure Title Author
2026-03-04 [Corrected description]Registration Statement (Equity securities) 이뮨온시아
2026-03-04 [Corrected description]Decision on Capital Increase with Consideration 이뮨온시아
2026-02-27 Report on status of specific securities, etc. owned by executives and major shareholders PAIK SOONMYUNG
2026-02-24 Request for Submission of Correction Report( 2026.02.09. 제출 증권신고서(지분증권) ) 금융감독원
2026-02-23 Notice on Investor Relations 이뮨온시아
2026-02-09 [Requested submission of correction]Registration Statement (Equity securities) 이뮨온시아
2026-02-06 Decision on Capital Increase with Consideration 이뮨온시아
2026-02-06 Resolutions for Convocation of General Meeting of Shareholders 이뮨온시아
2026-02-06 30% or More Change in Sales or Profit/Loss(15% or more in the case of large-scale corporations) 이뮨온시아
2025-12-16 Closure of Register of Shareholders or Designation of Record Date 이뮨온시아
1 2 3 4 5